Abstract
AbstractThe Cervical Screening Cohort enrols women screened for human papillomavirus (HPV) and cervical abnormalities within the capital region of Sweden from the organised screening program and the non-organised testing of cervical samples. The cohort started in 2011 and has enrolled more than 670,000 women, contributing with more than 1.2 million biobanked samples. The cohort is systematically updated with individual-level data from the Swedish National Cervical Screening Registry (NKCx). Key variables include birthdate, sampling date, cytological, histopathological and HPV analysis results, and invitation history. Each sampling and subsequent clinical follow-up is sequentially registered, allowing for longitudinal analyses of screening results and associated results of the clinical workup. The cohort is ideal for longitudinal, long-term follow-up studies due to its validated documentation and registry-derived information. From the data, it is possible to penetrate important human health mechanisms. The data are available as open-data and GDPR-compliant. Samples are available after getting the required permissions. Results will help researchers understand factors that increase cancer risk and other diseases.
Funder
EC | Horizon 2020 Framework Programme
Vetenskapsrådet
Sveriges Kommuner och Landsting
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. National Board of Health and Welfare, 2022. Screening for Cervical Cancer -
2. Recommendation to offer screening. 2022-2-7758. Available from https://www.socialstyrelsen.se. [Accessed May 22, 2023].
3. Perskvist, N., Norman, I., Eklund, C., Litton, J. E. & Dillner, J. The Swedish cervical cytology biobank: sample handling and storage process. Biopreserv Biobank. 11, 19–24, https://doi.org/10.1089/bio.2012.0036 (2013).
4. Perskvist, N., Björklund, C. & Dillner, J. A complex intervention for workflow enhancement at the Swedish cervical cytology biobank. Biopreservation and Biobanking. 12, 69–73 (2014).
5. Barrett, J. et al. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat. Commun. 13, 449, https://doi.org/10.1038/s41467-021-27918-w (2022).